Joaquim Bosch-Barrera

Summary

Country: Spain

Publications

  1. pmc Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo
    Sílvia Cufí
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Sci Rep 3:2459. 2013
  2. doi request reprint Direct antitumour activity of zoledronic acid: preclinical and clinical data
    Joaquim Bosch-Barrera
    Catalan Institute of Oncology, Dr Josep Trueta University Hospital, Girona, Spain
    Clin Transl Oncol 13:148-55. 2011
  3. doi request reprint Costs and ethical issues related to first-line treatment of metastatic non-small-cell lung cancer: considerations from a public healthcare system perspective
    Joaquim Bosch-Barrera
    Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain
    Clin Lung Cancer 12:335-40. 2011
  4. pmc Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin
    Bruna Corominas-Faja
    Metabolism and Cancer Group Translational Research Laboratory Catalan Institute of Oncology Girona, Catalonia, Spain Girona Biomedical Research Institute IDIBGi Girona, Catalonia, Spain
    Cell Cycle 12:3390-404. 2013
  5. ncbi request reprint Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells
    Sílvia Cufí
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain Girona Biomedical Research Institute IdIBGi, Girona, Catalonia, Spain
    Food Chem Toxicol 60:360-8. 2013
  6. doi request reprint Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205
    Sílvia Cufí
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Cell Cycle 11:1235-46. 2012
  7. pmc IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations
    Alejandro Vazquez-Martin
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Sci Rep 3:2560. 2013
  8. doi request reprint Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation
    Cristina Oliveras-Ferraros
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Cell Cycle 11:865-70. 2012
  9. pmc Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment
    Javier A Menendez
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Oncotarget 5:2344-8. 2014
  10. pmc Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts
    Sílvia Cufí
    Translational Research Laboratory, Catalan Institute of Oncology ICO, Girona, Spain
    Oncotarget 3:395-8. 2012

Collaborators

Detail Information

Publications13

  1. pmc Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo
    Sílvia Cufí
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Sci Rep 3:2459. 2013
    ....
  2. doi request reprint Direct antitumour activity of zoledronic acid: preclinical and clinical data
    Joaquim Bosch-Barrera
    Catalan Institute of Oncology, Dr Josep Trueta University Hospital, Girona, Spain
    Clin Transl Oncol 13:148-55. 2011
    ..Translational questions regarding drug dose, dose interval, and sequence with chemotherapy treatment are also addressed...
  3. doi request reprint Costs and ethical issues related to first-line treatment of metastatic non-small-cell lung cancer: considerations from a public healthcare system perspective
    Joaquim Bosch-Barrera
    Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain
    Clin Lung Cancer 12:335-40. 2011
    ..These considerations have been examined from the perspective of a national public healthcare system...
  4. pmc Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin
    Bruna Corominas-Faja
    Metabolism and Cancer Group Translational Research Laboratory Catalan Institute of Oncology Girona, Catalonia, Spain Girona Biomedical Research Institute IDIBGi Girona, Catalonia, Spain
    Cell Cycle 12:3390-404. 2013
    ..Our findings highlight the benefit of administration of silibinin in combination with EGFR TKIs to target CSCs and minimize the ability of tumor cells to escape cell death in EGFR-mutant NSCLC patients...
  5. ncbi request reprint Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells
    Sílvia Cufí
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain Girona Biomedical Research Institute IdIBGi, Girona, Catalonia, Spain
    Food Chem Toxicol 60:360-8. 2013
    ....
  6. doi request reprint Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205
    Sílvia Cufí
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Cell Cycle 11:1235-46. 2012
    ....
  7. pmc IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations
    Alejandro Vazquez-Martin
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Sci Rep 3:2560. 2013
    ....
  8. doi request reprint Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation
    Cristina Oliveras-Ferraros
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Cell Cycle 11:865-70. 2012
    ..Restored antigenicity and immunogenicity of tumor cells may represent a previously unrecognized primary mode of action underlying the cancer-preventive effects of metformin...
  9. pmc Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment
    Javier A Menendez
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Oncotarget 5:2344-8. 2014
    ..Perhaps then, the oncobiguanides, as we call them here, could be viewed as a mechanistically different type of anti-cancer drugs employed at doses notably higher than those used chronically when functioning as diabetobiguanides. ..
  10. pmc Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts
    Sílvia Cufí
    Translational Research Laboratory, Catalan Institute of Oncology ICO, Girona, Spain
    Oncotarget 3:395-8. 2012
    ....
  11. doi request reprint Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment
    Cristina Oliveras-Ferraros
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Oncol Rep 27:1887-92. 2012
    ....
  12. pmc Metformin: multi-faceted protection against cancer
    Sonia del Barco
    Medical Oncology, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Oncotarget 2:896-917. 2011
    ..Current and future clinical trials will elucidate whether metformin has the potential to be used in preventive and treatment settings as an adjuvant to current cancer therapeutics...
  13. doi request reprint The multimodal management of locally advanced N2 non-small cell lung cancer: is there a role for surgical resection? A single institution's experience
    Joaquim Bosch-Barrera
    Department of Medical Oncology, Clinica Universidad de Navarra, 31008, Pamplona, Spain
    Clin Transl Oncol 14:835-41. 2012
    ..We present our institution's experience with the management of stage III (N2) NSCLC patients, analyzing whether the addition of surgery improves survival when compared with definitive CT-RT alone...